Search

Your search keyword '"Troya, Jesús"' showing total 205 results

Search Constraints

Start Over You searched for: Author "Troya, Jesús" Remove constraint Author: "Troya, Jesús"
205 results on '"Troya, Jesús"'

Search Results

2. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

6. Epigenome-wide association study of COVID-19 severity with respiratory failure

8. Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study

12. 1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.

14. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

15. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

18. Epidemiological and Clinical Characteristics of Patients Admitted to a Secondary Hospital with Suspected MPOX Virus Infection: Is HIV Playing a Role?

21. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

22. Predict the effects of dolutegravir (DTG) plus lamivudine (3TC) on immunological responses in people living with HIV (PLWHIV)

23. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens

25. Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic

26. 1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain

27. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

28. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths

31. Dolutegravir plus rilpivirine: benefits beyond viral suppression

32. The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies

33. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

34. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

35. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

38. Effectiveness of an HIV care model integrated into addiction care based on medication-assisted treatment for HIV-positive people who use drugs.

39. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19.

40. HCV eradication with DAAs differently affects HIV males and females: A whole miRNA sequencing characterization

41. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19

42. Epigenome-wide association study of COVID-19 severity with respiratory failure

45. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naïve Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

46. Characteristics, complications and outcomes among 1549 patients hospitalised with COVID-19 in a secondary hospital in Madrid, Spain: a retrospective case series study

47. Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone

Catalog

Books, media, physical & digital resources